NYU CPM in the Media

Read articles, watch videos, and listen to podcasts featuring faculty and research from the NYU Langone Center for Psychedelic Medicine

JAMA Online: Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial

Read the results of a large clinical trial of psilocybin-assisted therapy for Major Depressive Disorder. Fun fact: NYU enrolled 19% of the participants for this multisite trial: the highest number of any of the other sites!

The Microdose: Does adding MDMA to psilocybin or LSD result in fewer bad trips?

In this week’s newsletter from the U.C. Berkeley Center for the Science of Psychedelics, you can read about our recent research on the effects of combining two common types of psychedelics. A collaboration with the team at Imperial College London’s Centre for Psychedelic Research, the study was led by Dr. Rick Zeifman from the NYU CPM.

MAPS Bulletin: Psychedelic Research
Finds a Home in Academia

Learn from Ali McGhee, CPM Director Dr. Michael Bogenschutz, and others about how NYU and other academic institutions across the country are training the next generation of psychedelic researchers and clinicians, including through our Psychedelic Research Training Program and tri-institutional consortium with Yale University and Johns Hopkins University.

L.A. Times on ketamine, the “legal psychedelic”

Learn more about ketamine-assisted psychotherapy in this newsletter from Los Angeles Times reporter Laura Newberry. In this piece, the third in a series on psychedelic medicine, Dr. Kelley O’Donnell and others discuss how ketamine is used within and outside the context of psychedelic-assisted psychotherapy, and the various strengths and limitations of different treatment models.

Informed Consent in Psychedelic Therapy Research: Why is it Complicated?

Watch the replay of this lively roundtable discussion from an event sponsored by Chacruna in partnership with the Project on Psychedelics Law and Regulation at the Petrie-Flom Center at Harvard Law School. The panel featured Dr. Kelley O’Donnell, Director of Clinical Training at the CPM, and colleagues as they discuss the topic of consent in psychedelic therapy.

New York Times: Psilocybin Therapy Sharply Reduces Excessive Drinking

Read coverage in the NYT about our landmark study of psilocybin-assisted therapy for alcohol use disorder, led by Dr. Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine and the Principal Investigator on the multisite trial.

Business Insider: Universities are teaming up to tackle a key bottleneck

Learn about the tri-institutional consortium bringing together clinicians and researchers at NYU, Yale, and Johns Hopkins, to generate psychedelics-related curricular content for the next generation of psychiatrists in the coming age of psychedelic medicine!

Time Magazine: Psilocybin Could be a Therapeutic Breakthrough For Addiction

Learn more about how psychedelics are entering mainstream medicine, in part through the research of Dr. Michael Bogenschutz, Director of the NYU Center for Psychedelic Medicine!

Everyday Health: What Are Psychedelic Drugs, and How Can They Help Treat Mental Illness?

Read an introduction to psychedelics and psychedelic medicine, featuring Dr. Kelley O’Donnell from the NYU CPM, as well as other prominent psychedelic researchers!

Psychology Today: Wholeness and healing in psychedelic therapy

Read this Psychology Today profile to learn more about the work of Dr. Kelley O’Donnell, who is the Director of Clinical Training at the NYU CPM and one of our most experienced psychedelic therapists!

The New Yorker: The Trip Treatment

Learn more about psychedelic experiences and research in this piece from The New Yorker, in which Michael Pollan quotes Dr. Stephen Ross, Associate Director of the NYU CPM, and discusses some of the groundbreaking studies led by him and by Dr. Michael Bogenschutz, Director of the NYU CPM.

New York Times: Psilocybin for Cancer-Associated Anxiety and Depression

Read NYT coverage of our 2016 paper on psilocybin-assisted therapy for cancer-associated anxiety and depression, and learn more about participants’ experiences!